论文部分内容阅读
目的：探讨溶栓、抗凝治疗ST段抬高型心肌梗塞的临床效果及安全性。方法取我院内科80例符合标准的患者随机分为观察组（n＝56）和对照组（n＝24）。观察组在12小时内给予尿激酶100－150万U静脉滴注溶栓，30min内滴完；之后皮下注射低分子肝素钙5000IU、bid抗凝，同时给予常规治疗。对照组只给予常规治疗。结果观察组治疗冠脉再通率为85．7％，病死率3．5％，再出血率7．1％；对照组治疗冠脉再通率33．3％，病死率25％，再出血率4．2％。差异有统计学意义（p＜0．05）。结论溶栓、抗凝在ST段抬高型心肌梗塞的治疗中疗效显著，但再出血并发症相应增多。“,”Objective To investigate the clinical ef ect and safety of thrombolysis,anticoagulation therapy in ST segment elevation myocardial infarction.Methods the Department of inter-nal medicine in our hospital,80 patients were randomly divided into standard into the observation group (n=56)and control group (n=24).The observation group in 12 hours by giving uroki-nase intravenous thrombolytic therapy of 100-150 mil ion U,30min infusion;after subcutaneous injection of low molecular heparin calcium 5000IU,bid anticoagulation,and routine therapy.The control group was given conventional treatment.Results the observation group treatment of coronary recanalization rate was 85.7%,the mortality rate was 3.5%,the rate of rebleeding was 7.1%;the control group for the treatment of coronary artery recanalization rate was 33.3%,the mortality rate was 25%,the rate of rebleeding in 4.2%.The dif erence was statistical y signifi-cant (p<0.05).Conclusion thrombolysis and anticoagulation significant eficacy in the treatment ofST segment elevation myocardial infarction,but the corresponding increase in bleeding com-plications.